SiteSpecificInVivoT Site-specific in vivo T cell engineering
- Coordinator
- Tel Aviv University, Israel
- Runs
- 1 July 2026 to 31 December 2027
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101335115
What the project is doing
In the project's own words, from its summary on CORDIS.
CAR T cells are clinically effective in hematological malignancies and autoimmune diseases. Marketed therapies rely on ex vivo T cell engineering, performed in specialized centres only. In vivo T cell engineering may profoundly reduce timelines and expenses. Most current methods for in vivo T cell engineering use either promiscuously integrating vectors, bearing risk of insertional mutagenesis, or CAR mRNA in LNPs, conferring a transient effect only.
Here, we establish in vivo gene targeting in T cells by co-delivering a CAR homologous recombination cassette in a single vector together with a site-specific meganuclease specifically designed to cleave the human TRAC locus. We further develop a dual vector approach utilizing CRISPR/Cas9. In addition, we incorporate in the capsid of our AAV, designed ankyrin repeat proteins (DARPins) targeting the human CD3, CD4 or CD8 receptors.
We present preliminary supporting results and outline the development plan for engineering T cells in vivo using a single injection of a CD8-directed AAV. We aim to provide the first demonstration of in vivo CAR T cell engineering by site-specific gene targeting, a paradigm shift for cellular immunotherapies, with fast translation into the clinic and the market. We plan to show tumor eradication in both immunocompetent animals and humanized mice.
Our studies will include safety evaluations, such as mice vital signs monitoring tracking of AAV biodistribution, off-target cleavage and chromosomal aberrations. We will pursue a protect-then-partner route, filing priority and PCT patents, obtaining an FTO opinion, and assembling a diligence-ready data room. We will engage cell/gene-therapy sponsors and CDMOs for field-of-use licensing, keeping a spin-out option for broad exclusivity.
We will seek regulatory advice to align on nonclinical and CMC expectations. Milestones include priority filing, FTO opinion, ≥5 BD meetings with ≥2 LoIs/LoSs, and a partnering term sheet/option by project end.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Tel Aviv University | Tel Aviv | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI